Core Viewpoint - XinNuoWei (300765) announced that its subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SYS6023, an antibody-drug conjugate targeting HER3, aimed at treating unresectable locally advanced or metastatic breast cancer [1] Group 1 - The SYS6023 drug is designed to utilize a self-developed topoisomerase I inhibitor payload, which is expected to avoid drug resistance through efflux mechanisms [1]

Core Viewpoint - XinNuoWei (300765.SZ) announced that its subsidiary, Giant Stone Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SYS6023, a HER3-targeted antibody-drug conjugate [1] Group 1 - SYS6023 is designed to target specific receptors on tumor surfaces and utilizes a topoisomerase I inhibitor developed by the company as its payload [1] - The mechanism of SYS6023 involves binding to tumor cells, entering them through endocytosis, and releasing toxins to kill cancer cells [1] - The payload of SYS6023 is not a substrate for efflux pumps, which is expected to help avoid resistance issues commonly seen with DXd class ADCs [1]

Core Viewpoint - The company XinNuoWei (300765.SZ) announced that its subsidiary, Giant Stone Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SYS6023, a HER3-targeted antibody-drug conjugate [1] Group 1 - SYS6023 is designed to target specific receptors on tumor surfaces and utilizes a topoisomerase I inhibitor developed by the company as its payload [1] - The mechanism of SYS6023 involves binding to tumor cells, entering them through endocytosis, and releasing toxins to kill cancer cells [1] - The payload of SYS6023 is not a substrate for efflux pumps, which is expected to help avoid resistance issues commonly seen with DXd class ADCs [1]